[Sentinel lymph node in low stage cervical cancers. Current data. Quality assurance. Prospects]

Fabrice Lécuru; Anne-Sophie Bats; Cherazade Bensaid; Nathalie Douay Hauser; Julien Seror; Claude Nos; Patrice Mathevet

doi:10.1684/bdc.2014.1928

[Sentinel lymph node in low stage cervical cancers. Current data. Quality assurance. Prospects]

Bull Cancer. 2014 Apr;101(4):349-53. doi: 10.1684/bdc.2014.1928.

[Article in French]

Authors

Fabrice Lécuru¹, Anne-Sophie Bats¹, Cherazade Bensaid¹, Nathalie Douay Hauser¹, Julien Seror¹, Claude Nos¹, Patrice Mathevet²

Affiliations

¹ AP-HP, Hôpital Européen Georges-Pompidou, Centre expert oncologie gynécologique Paris Descartes, 20 rue Leblanc 75015, Paris France, Université Paris Descartes, Sorbonne Paris Cité, Faculté de médecine, 12, rue de l'École-de-Médecine, 75006 Paris,, Université Paris Descartes, Faculté de médecine, UMRS 747, 12, rue de l'École-de-Médecine, 75006 Paris, France.
² UNIL Lausanne, CHU Vaudois, Service de gynécologie, Rue du Bugnon 46, 1011 Lausanne, Suisse.

PMID: 24793625
DOI: 10.1684/bdc.2014.1928

Abstract

Sentinel node biopsy appears as a promising technique for the assessment of nodal disease in early cervical cancers. Selection of a population with a low risk of nodal metastasis, a minimal training, and simple rules allow a low false negative rate. Sentinel node biopsy provides supplementary information, such as anatomical information (nodes outside of routine lymphadenectomy areas) and histological information (isolated tumors cells and micrometastases).

Keywords: cervical cancer; false negative rate; micrometastasis; sentinel node biopsy.

Publication types

English Abstract
Review

MeSH terms

Cervix Uteri / pathology*
Female
Humans
Lymph Nodes / pathology*
Lymphatic Metastasis
Neoplasm Micrometastasis / pathology
Neoplasm Staging / methods
Patient Selection
Sentinel Lymph Node Biopsy*
Uterine Cervical Neoplasms / pathology*